Interim Data From Phase II Study of Combination Regimens Including VX-222, Incivek Suggest Potential to Treat Genotype 1 Hepatitis C

July 27, 2011
Vertex Pharmaceuticals announced interim results from ZENITH, an ongoing Phase II study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (400 mg or 100 mg) in combination with Incivek (telaprevir) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.
Financial Post